Wound healing is a core skill in dermatology, but true expertise involves incorporating new techniques with medical school ...

Ourself, a leader in the next generation of skincare, today announced that clinical data evaluating Ourself's patented delivery technology, Tiered-Release Vesicles™ (TRVs), was published in ...

L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- . (“Checkpoint”) ...

While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have ...

Estrogen and progesterone combined in OCs act in a synergistic manner in the gonadotropin axis. They decrease the secretion of hypophysial-luteinizing hormone and follicle-stimulating hormone by ...

Attendees were provided with a variety of clinical and practice management tracks, while aspiring veterinarians received ...

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Minnesota through its partnership ...

Advancements in life sciences have heightened public understanding of dermatology, emphasizing the importance of ...

cSCC remains a disease with a significant need for more effective and tolerable treatment options, particularly for patients with concomitant hematological malignancies, solid organ transplant ...

Onquality Pharmaceuticals China Ltd. has synthesized prodrugs of tofacitinib acting as JAK inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis and alopecia areata.

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...